scholarly journals Development of novel DNA vaccine for VEGF in murine cancer model

2013 ◽  
Vol 3 (1) ◽  
Author(s):  
Mariko Kyutoku ◽  
Hironori Nakagami ◽  
Hiroshi Koriyama ◽  
Hideki Tomioka ◽  
Futoshi Nakagami ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
Cancer Model ◽  
Murine Cancer Model

scholarly journals Peptide drugs for photopharmacology: how much of a safety advantage can be gained by photocontrol?

2020 ◽  
Vol 2 (1) ◽  
pp. FDD28 ◽  
Author(s):  
Oleg Babii ◽  
Sergii Afonin ◽  
Tim Schober ◽  
Liudmyla V Garmanchuk ◽  
Liudmyla I Ostapchenko ◽  
...  
Keyword(s):  
Chemotherapeutic Agent ◽  
In Vitro Cytotoxicity ◽  
Pharmacokinetic Parameters ◽  
Cancer Model ◽  
Pharmacokinetic Properties ◽  
Insight Into ◽  
Safety Advantage ◽  
Murine Cancer Model

Aim: To verify whether photocontrol of biological activity could augment safety of a chemotherapeutic agent. Materials & methods: LD50 values for gramicidin S and photoisomeric forms of its photoswitchable diarylethene-containing analogs were determined using mice. The results were compared with data obtained from cell viability measurements taken for the same compounds. Absorption, Distribution, Metabolism, and Elimination (ADME) tests using a murine cancer model were conducted to get insight into the underlying reasons for the observed in vivo toxicity. Results: While in vitro cytotoxicity values of the photoisomers differed substantially, the differences in the observed LD50 values were less pronounced due to unfavorable pharmacokinetic parameters. Conclusion: Despite unfavorable pharmacokinetic properties as in the representative case studied here, there is an overall advantage to be gained in the safety profile of a chemotherapeutic agent via photocontrol. Nevertheless, optimization of the pharmacokinetic parameters of photoisomers is an important issue to be addressed during the development of photopharmacological drugs.

scholarly journals DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model

Gene Therapy ◽  
2014 ◽  
Vol 21 (10) ◽  
pp. 888-896 ◽  
Author(s):  
T-Y Weng ◽  
M-C Yen ◽  
C-T Huang ◽  
J-J Hung ◽  
Y-L Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Transgenic Mouse ◽  
Dna Vaccine ◽  
Mouse Lung ◽  
Cancer Model ◽  
Antitumor Response ◽  
Lung Cancer Model

scholarly journals Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells

2015 ◽  
Vol 33 (6) ◽  
pp. 2947-2953 ◽  
Author(s):  
TAKANOBU MOTOSHIMA ◽  
YOSHIHIRO KOMOHARA ◽  
HASITA HORLAD ◽  
ARIO TAKEUCHI ◽  
YOSHIHIRO MAEDA ◽  
...  
Keyword(s):  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Cancer Model ◽  
Antitumor Effects ◽  
Murine Cancer Model

scholarly journals Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

2016 ◽  
Vol 197 (4) ◽  
pp. 1477-1488 ◽  
Author(s):  
Katherine A. Waugh ◽  
Sonia M. Leach ◽  
Brandon L. Moore ◽  
Tullia C. Bruno ◽  
Jonathan D. Buhrman ◽  
...  
Keyword(s):  
T Cell ◽  
Cd8 T Cell ◽  
Molecular Profile ◽  
Cancer Model ◽  
Murine Cancer Model

scholarly journals Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model

2010 ◽  
Vol 15 (6) ◽  
pp. 977-984 ◽  
Author(s):  
Nafiseh Pakravan ◽  
Ladan Langroudi ◽  
Monire Hajimoradi ◽  
Zuhair Mohammad Hassan
Keyword(s):  
Breast Cancer ◽  
Dna Vaccine ◽  
Cancer Model ◽  
Her2 Breast Cancer ◽  
Breast Cancer Model

scholarly journals The mechanisms of action of Plasmodium infection against cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Xiaoping Chen ◽  
Li Qin ◽  
Wen Hu ◽  
Dickson Adah
Keyword(s):  
Public Health ◽  
Immune Checkpoint Blockade ◽  
Mechanisms Of Action ◽  
Plasmodium Infection ◽  
Cancer Model ◽  
Model Studies ◽  
Tumor Bearing ◽  
Tumor Growth And Metastasis ◽  
Immunosuppressive Microenvironment ◽  
Murine Cancer Model

AbstractOur murine cancer model studies have demonstrated that Plasmodium infection activates the immune system that has been inhibited by cancer cells, counteracts tumor immunosuppressive microenvironment, inhibits tumor angiogenesis, inhibits tumor growth and metastasis, and prolongs the survival time of tumor-bearing mice. Based on these studies, three clinical trials of Plasmodium immunotherapy for advanced cancers have been approved and are ongoing in China. After comparing the mechanisms of action of Plasmodium immunotherapy with those of immune checkpoint blockade therapy, we propose the notion that cancer is an ecological disease and that Plasmodium immunotherapy is a systemic ecological counterattack therapy for this ecological disease, with limited side effects and without danger to public health based on the use of artesunate and other measures. Recent reports of tolerance to treatment and limitations in majority of patients associated with the use of checkpoint blockers further support this notion. We advocate further studies on the mechanisms of action of Plasmodium infection against cancer and investigations on Plasmodium-based combination therapy in the coming future.

Sign in / Sign up

Export Citation Format

Share Document